Regression of Peritubular Capillaries Coincides with Angiogenesis and Renal Cyst Growth in Experimental Polycystic Kidney Disease

References

• Rizk DV, Chapman AB. 41 - polycystic and other cystic kidney diseases In: Gilbert SJ, Weiner DE, editors. National Kidney Foundation Primer on Kidney Diseases (Sixth Edition). Philadelphia: W.B. Saunders; 2014:362–370.
   Google Scholar
• Wilson PD. Polycystic kidney disease. N Engl J Med. 2004;350(2):151–164. doi:10.1056/NEJMra02216114711914
   PubMed Web of Science ®Google Scholar
• Torres VE, Harris PC. Mechanisms of disease: autosomal dominant and recessive polycystic kidney diseases. Nat Clin Pract Nephrol. 2006;2(1):40–55. doi:10.1038/ncpneph007016932388
   PubMedGoogle Scholar
• Patel V, Li L, Cobo-stark P, et al. Acute kidney injury and aberrant planar cell polarity induce cyst formation in mice lacking renal cilia. Hum Mol Genet. 2008;17(11):1578–1590. doi:10.1093/hmg/ddn04518263895
   PubMed Web of Science ®Google Scholar
• Herzlinger D, Hurtado R. Patterning the renal vascular bed. Semin Cell Dev Biol. 2014;36:50–56. doi:10.1016/j.semcdb.2014.08.00225128732
   PubMed Web of Science ®Google Scholar
• Moffat DB, Fourman J. A vascular pattern of the rat kidney. 1963. J Am Soc Nephrol. 2001;12(3):624–632.11181813
   PubMed Web of Science ®Google Scholar
• Bankir L, De Rouffignac C. Urinary concentrating ability: insights from comparative anatomy. Am J Physiol Regul Integr Comp Physiol. 1985;18(6):R643–R666. doi:10.1152/ajpregu.1985.249.6.R643
   Web of Science ®Google Scholar
• Bello-Reuss E, Holubec K, Rajaraman S. Angiogenesis in autosomal-dominant polycystic kidney disease. Kidney Int. 2001;60(1):37–45. doi:10.1046/j.1523-1755.2001.00768.x11422734
   PubMed Web of Science ®Google Scholar
• Wei W, Popov V, Walocha JA, Wen J, Bello-Reuss E. Evidence of angiogenesis and microvascular regression in autosomal-dominant polycystic kidney disease kidneys: a corrosion cast study. Kidney Int. 2006;70(7):1261–1268. doi:10.1038/sj.ki.500172516883324
   PubMed Web of Science ®Google Scholar
• Reed BY, Masoumi A, Elhassan E, et al. Angiogenic growth factors correlate with disease severity in young patients with autosomal dominant polycystic kidney disease. Kidney Int. 2011;79(1):128–134. doi:10.1038/ki.2010.35520881939
   PubMed Web of Science ®Google Scholar
• Martins DP, Souza MA, Baitello ME, et al. Vascular endothelial growth factor as an angiogenesis biomarker for the progression of autosomal dominant polycystic kidney disease. Genet Mol Res. 2016;15(1). doi:10.4238/gmr.15017623.
   Web of Science ®Google Scholar
• Grantham JJ, Geiser JL, Evan AP. Cyst formation and growth in autosomal dominant polycystic kidney disease. Kidney Int. 1987;31(5):1145–1152. doi:10.1038/ki.1987.1213599654
   PubMed Web of Science ®Google Scholar
• Raptis V, Bakogiannis C, Loutradis C, et al. Levels of Endocan, Angiopoietin-2, and Hypoxia-inducible factor-1a in patients with autosomal dominant polycystic kidney disease and different levels of renal function. Am J Nephrol. 2018;47(4):231–238. doi:10.1159/00048811529597186
   PubMed Web of Science ®Google Scholar
• Ta MH, Schwensen KG, Foster S, et al. Effects of TORC1 inhibition during the early and established phases of polycystic kidney disease. PLoS One. 2016;11(10):e0164193. doi:10.1371/journal.pone.016419327723777
   PubMed Web of Science ®Google Scholar
• Zafar I, Ravichandran K, Belibi FA, Doctor RB, Edelstein CL. Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease. Kidney Int. 2010;78(8):754–761. doi:10.1038/ki.2010.25020686448
   PubMed Web of Science ®Google Scholar
• Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor.[see comment]. Nat Med. 2002;8(2):128–135. doi:10.1038/nm0202-12811821896
   PubMed Web of Science ®Google Scholar
• Semela D, Piguet A-C, Kolev M, et al. Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. J Hepatol. 2007;46(5):840–848. doi:10.1016/j.jhep.2006.11.02117321636
   PubMed Web of Science ®Google Scholar
• McCooke JK, Appels R, Barrero RA, et al. A novel mutation causing nephronophthisis in the Lewis polycystic kidney rat localises to a conserved RCC1 domain in Nek8. BMC Genomics. 2012;13(1):393. doi:10.1186/1471-2164-13-39322899815
   PubMed Web of Science ®Google Scholar
• Phillips JK, Hopwood D, Loxley RA, et al. Temporal relationship between renal cyst development, hypertension and cardiac hypertrophy in a new rat model of autosomal recessive polycystic kidney disease. Kidney Blood Press Res. 2007;30(3):129–144. doi:10.1159/00010182817446713
   PubMed Web of Science ®Google Scholar
• Smith LA, Bukanov NO, Husson H, et al. Development of polycystic kidney disease in juvenile cystic kidney mice: insights into pathogenesis, ciliary abnormalities, and common features with human disease. J Am Soc Nephrol. 2006;17(10):2821–2831. doi:10.1681/ASN.200602013616928806
   PubMed Web of Science ®Google Scholar
• Zhang JQJ, Burgess J, Stepanova D, et al. Role of cyclin-dependent kinase 2 on the progression of juvenile cystic kidney disease mice. Lab Invest. 2020. doi:10.1038/s41374-019-0360-4
   Web of Science ®Google Scholar
• Wahl PR, Serra AL, Le Hir M, Molle KD, Hall MN, Wuthrich RP. Inhibition of mTOR with sirolimus slows disease progression in Han: SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant. 2006;21(3):598–604. doi:10.1093/ndt/gfi18116221708
   PubMed Web of Science ®Google Scholar
• Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol. 2006;17(1):17–25. doi:10.1681/ASN.200507075716291837
   PubMed Web of Science ®Google Scholar
• Kang DH, Kanellis J, Hugo C, et al. Role of the microvascular endothelium in progressive renal disease. J Am Soc Nephrol. 2002;13(3):806–816. doi:10.1097/01.ASN.0000034910.58454.FD11856789
   PubMed Web of Science ®Google Scholar
• Bernhardt WM, Wiesener MS, Weidemann A, et al. Involvement of hypoxia-inducible transcription factors in polycystic kidney disease. Am J Pathol. 2007;170(3):830–842. doi:10.2353/ajpath.2007.06045517322369
   PubMed Web of Science ®Google Scholar
• Zeier M, Fehrenbach P, Geberth S, Mohring K, Waldherr R, Ritz E. Renal histology in polycystic kidney disease with incipient and advanced renal failure. Kidney Int. 1992;42(5):1259–1265. doi:10.1038/ki.1992.4131453612
   PubMed Web of Science ®Google Scholar
• Tao Y, Kim J, Yin Y, et al. VEGF receptor inhibition slows the progression of polycystic kidney disease. Kidney Int. 2007;72(11):1358–1366. doi:10.1038/sj.ki.500255017882148
   PubMed Web of Science ®Google Scholar
• Rabelink TJ, Wijewickrama DC, de Koning EJ. Peritubular endothelium: the Achilles heel of the kidney? Kidney Int. 2007;72(8):926–930. doi:10.1038/sj.ki.500241417609688
   PubMed Web of Science ®Google Scholar
• Dome B, Hendrix MJC, Paku S, Tovari J, Timar J. Alternative vascularization mechanisms in cancer: pathology and therapeutic implications. Am J Pathol. 2007;170(1):1–15. doi:10.2353/ajpath.2007.06030217200177
   PubMed Web of Science ®Google Scholar
• Coban M, Inci A. The association of serum angiogenic growth factors with renal structure and function in patients with adult autosomal dominant polycystic kidney disease. Int Urol Nephrol. 2018;50(7):1293–1300. doi:10.1007/s11255-018-1866-129654395
   PubMed Web of Science ®Google Scholar
• Faes S, Santoro T, Demartines N, Dormond O. Evolving significance and future relevance of anti-angiogenic activity of mTOR inhibitors in cancer therapy. Cancers. 2017;9(11):152. doi:10.3390/cancers9110152
   Web of Science ®Google Scholar
• Dormond-Meuwly A, Roulin D, Dufour M, Benoit M, Demartines N, Dormond O. The inhibition of MAPK potentiates the anti-angiogenic efficacy of mTOR inhibitors. Biochem Biophys Res Commun. 2011;407(4):714–719. doi:10.1016/j.bbrc.2011.03.08621439267
   PubMed Web of Science ®Google Scholar